RT Journal Article
SR Electronic
T1 Heterogeneity of acetylcholine receptor autoantibody-mediated complement activity in patients with myasthenia gravis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.05.21264566
DO 10.1101/2021.10.05.21264566
A1 Obaid, Abeer H.
A1 Zografou, Chryssa
A1 Vadysirisack, Douangsone D.
A1 Munro-Sheldon, Bailey
A1 Fichtner, Miriam L.
A1 Philbrick, William M.
A1 Bennett, Jeffrey L.
A1 Nowak, Richard J.
A1 O’Connor, Kevin C.
YR 2021
UL http://medrxiv.org/content/early/2021/10/07/2021.10.05.21264566.abstract
AB Background Autoantibodies targeting the acetylcholine receptor (AChR) in the serum of myasthenia gravis (MG) patients are broadly polyclonal and heterogeneous in their pathogenic capacity. Specifically, AChR autoantibody-mediated pathology occurs through three mechanisms that include complement-directed tissue damage, blocking of the acetylcholine binding site on the AChR, and modulation (internalization) of the AChR. Clinical assays used for diagnosis and prognosis measure only AChR autoantibody binding and they provide weak association with disease burden, thereby limiting understanding of mechanistic heterogeneity, and monitoring therapeutic response.Objective To develop an in-vitro cell-based assay that measures AChR autoantibody-mediated complement membrane attack complex (MAC) formation.Methods A HEK293T cell line, which is commonly used for live cell-based AChR autoantibody binding assays, was modified such that the expression of the complement regulator genes (CD46, CD55 and CD59) were disrupted using CRISPR/Cas9 genome editing. This modified cell line was used to measure serum AChR autoantibody-mediated complement MAC formation via flow cytometry.Results AChR autoantibody-mediated MAC formation required the use of a modified HEK293T cell line in which the surface expression of three complement regulator genes was absent. Serum samples (n=155) from 97 clinically confirmed AChR patients were tested along with 32 healthy donor (HD) samples; the MG cohort included a wide range of disease burden and AChR autoantibody titer. AChR autoantibodies were detected in 139 of the 155 (89.7%) AChR patient samples via a live cell-based assay. Of the 139 AChR positive samples, autoantibody-mediated MAC formation was detected in 83 (59.7%), while no autoantibodies or MAC formation was detected in samples from the HD group. Autoantibody-mediated MAC formation positively associated with autoantibody binding in most MG patient samples. However, a subset displayed a disassociation between binding and MAC formation.Conclusions We demonstrate the development of a novel assay for evaluating AChR autoantibody-mediated complement activity. It is anticipated that this assay will afford a deeper understanding of the heterogeneous disease pathology and allow for the identification of MG patients who may benefit from complement inhibitor therapy.Competing Interest StatementAbeer H. Obaid reports no disclosures. Dr. Chryssa Zografou reports no disclosures. Dr. Douangsone D. Vadysirisack is an employee of UCB Ra Pharma. Dr. Bailey Munro-Sheldon reports no disclosures. Dr. Miriam L. Fichtner reports no disclosures. Dr. William M. Philbrick reports no disclosures. Dr. Jeffrey L. Bennett reports payment consultation fees for study design/consultation from Viela Bio, now part of Horizon Therapeutics; and personal fees from Mitsubishi Tanabe Pharma Corporation; Reistone Bio, AbbVie, Alexion; Chugai, Clene Nanomedicine, Genentech, Genzyme, Mitsubishi-Tanabe, and Roche; grants from Novartis, Mallinckrodt; and has a patent for Aquaporumab issued. Dr. Richard J. Nowak has received research support from the National Institutes of Health (NIH), Genentech, Alexion Pharmaceuticals, argenx, Annexon Biosciences, UCB Ra Pharmaceuticals, Myasthenia Gravis Foundation of America, Momenta, Immunovant, Grifols, and Viela Bio, now part of Horizon Therapeutics. RJN has served as consultant/advisor for Alexion Pharmaceuticals, argenx, Cabaletta Bio, CSL Behring, Grifols, Ra Pharmaceuticals, now a part of UCB Pharma, Immunovant, Momenta, and Viela Bio, now part of Horizon Therapeutics. Dr. Kevin C. OConnor has received research support from Ra Pharma, now part of UCB Pharma, and Alexion, now part of AstraZeneca and Viela Bio, now part of Horizon therapeutics. KCO is a consultant and equity shareholder of Cabaletta Bio, and is the recipient of a sponsored research subaward from the University of Pennsylvania, the primary financial sponsor of which is Cabaletta Bio. KCO has served as consultant/advisor for Alexion Pharmaceuticals, now part of AstraZeneca, and for Roche, and he has received speaking fees from Alexion, Roche, Genentech, and Viela Bio, now part of Horizon Therapeutics.Funding StatementKCO was supported by the National Institute of Allergy and Infectious Diseases of the NIH under award numbers R01-AI114780 and R21 AI164590; through an MGNet pilot grant awarded through the Rare Diseases Clinical Research Consortia of the NIH (award number U54-NS115054) and by a High Impact Clinical Research and Scientific Pilot Project award from the Myasthenia Gravis Foundation of American (MGFA). This project was supported, in part, by grants to KCO and RJN, from Ra Pharmaceuticals, now a part of UCB. JLB was supported by the National Eye Institute R01-EY022936 and R21-032399. MLF was supported in part by the SPIN award through Grifols and has further been supported by a DFG Research fellowship (FI 2471/1-1)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by Yale University's Institutional Review Board (clinicaltrials.gov || NCT03792659). Informed written consent was received from all participating patients prior to inclusion in this study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript will be made available to qualified investigators upon request, and upon completion of appropriate institutional MTA documentation.